'For quarter ending June 2024, consolidated Net sales (including other operating income) of Gland Pharma has increased 15.97% to Rs 1401.71 crore compared to quarter ended June 2023. Operating profit margin has declined from 24.32% to 18.86%, leading to 10.06% decline in operating profit to Rs 264.39 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 38.00% to 35.36%. Purchase of finished goods cost rose from 0.31% to 0.50%. Employee cost increased from 20.81% to 27.23%. Other expenses fell from 16.88% to 16.66%. Power and Oil fuel cost fell from 4.06% to 3.56%.
Other income rose 37% to Rs 51.43 crore. PBIDT fell 4.73% to Rs 315.82 crore. Provision for interest rose 14.23% to Rs 5.62 crore.
PBDT fell 5.02% to Rs 310.2 crore. Provision for depreciation rose 40.78% to Rs 91.96 crore.
Profit be...
Pleaselogin & subscribe to view the full report.
More Reports
-
Stable performance on growth, asset quality and margins
-
Margins improve, VNB rises
-
Strong performance with improved combined ratio
-
Revenue up 29% YoY, Net Profit up 28.9% YoY in Q3FY2025
|
|